Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore
01:15am, Wednesday, 11'th Feb 2026
Viking Therapeutics is advancing weight loss candidates through phase 2 and phase 3 trials. Results so far have been very promising.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
08:11pm, Tuesday, 10'th Feb 2026
Eli Lilly set the bar high, and it will be hard for other drugmakers to match its performance. Viking Therapeutics and Abivax are developing promising candidates.
The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short
06:03pm, Thursday, 05'th Feb 2026
Viking Therapeutics, Inc. faces significant challenges with VK2735, lacking differentiation from established obesity treatments like ZEPBOUND and WEGOVY. Phase 2 data highlight tolerability issues at
Head to Head Analysis: SAB Biotherapeutics (NASDAQ:SABS) versus Viking Therapeutics (NASDAQ:VKTX)
02:36am, Thursday, 05'th Feb 2026
Viking Therapeutics (NASDAQ: VKTX - Get Free Report) and SAB Biotherapeutics (NASDAQ: SABS - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two comp
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
04:05pm, Wednesday, 04'th Feb 2026
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharm
The Smartest Growth Stock to Buy With $30 Right Now
06:48pm, Tuesday, 03'rd Feb 2026
The recent success of Novo Nordisk and Eli Lilly validates a potential $150 billion obesity drug market. Viking Therapeutics is a year or two from launching a drug that can compete with industry leade
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
06:46pm, Friday, 30'th Jan 2026
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $29.06, signifying a -3.9% move from its prior day's close.
Viking Therapeutics to Report Q4 Earnings: Here's What to Know
09:50am, Friday, 30'th Jan 2026
VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.
2 Biotech Stocks Set to Rebound in 2026
01:15pm, Tuesday, 27'th Jan 2026
Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?
10:45am, Tuesday, 27'th Jan 2026
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?
11:15am, Monday, 26'th Jan 2026
Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade.
3 Growth Stocks to Invest $1,000 in Right Now
08:15pm, Saturday, 24'th Jan 2026
Shares of SoundHound AI have been all over the place of late, but that extreme volatility appears to have run its course. Viking Therapeutics wasn't the first name to the weight loss drug party.
The Best Stocks to Invest $40 in to Start the New Year Off Right
01:15pm, Saturday, 24'th Jan 2026
Pfizer's deep pipeline could prove its greatest asset, helping it bounce back. Viking Therapeutics is developing a highly promising weight loss medicine.
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
06:45pm, Friday, 23'rd Jan 2026
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.22, moving 5.49% from the previous trading session.
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
05:10am, Friday, 23'rd Jan 2026
Eli Lilly has skyrocketed due to its strength in the high-growth obesity drug market. One biotech company in particular may benefit from this market in just a few years.
